Virtual Online Video Live and Archived


Virtual Pharmaceutical and Medical Device Pricing and Payment Transformation Summit
June 16-19, 2026

Covering Tariffs, Most Favored Nation, TrumpRX, Direct to Consumer, Direct to Employer, Role of CMS & CMMI: GENEROUS, GLOBE, GUARD & BALANCE Models, IRA Medicare Drug Price Negotiations, Price Reporting, FDA Regulation, Medicaid Rebates, Medicare Fair Price, 340B and PBMs



Home

WATCH CMMI DIRECTOR ABE SUTTON’S INTERVIEW WITH APG’S VALINDA RUTLEDGE REGARDING NEW CMS/CMMI DRUG MODELS


FEATURED FACULTY

Shani Harmon Alexander, MS, JD

Senior Trade Counsel, Gilead; Former Director, Legal Manufacturing, Organon, Washington, DC

Heather Banuelos, JD

Counsel, King & Spalding LLP; Former FDA Counsel, Allergan; Former Associate Chief Counsel, US Food and Drug Administration, Washington, DC

Brian A. Bohnenkamp, MHA, JD

Partner, FDA and Life Sciences, King & Spalding, Washington, DC

Catherine Brandon, JD

Partner, Arnold & Porter; Senior Counsel, Office of the Assistant Secretary for Legislation, US Department of Health and Human Services, Washington, DC

Marijo G. Bustos, MBA

Head of Government Pricing & Reimbursement, UCB; Former Director, Prometic BioProduction & BioTherapeutics & Fresenius-Kabi USA, Smyrna, GA

Cindy Cerneka, MBA

Managing Director, Helio Health Group; Former Manager Government Reporting and Commercial Rebates, Mallinckrodt Pharmaceuticals, Durham, NC

Lanhee Chen, PhD

Fellow, Hoover Institution, Stanford; Former Counselor, HHS; Author, “Alternatives to Government-Imposed Price Controls to Lower US Drug Prices”, Stanford, CA

Chris Cobourn, MS

Managing Director and Government Programs (GP) Practice Lead, Helio Health Group, Placida, FL

John Coster, PhD, RPh

Former Director, Division of Pharmacy, & Senior Advisor, Medicare Drug Rebate & Negotiation Program, CMS, Fort Lauderdale, FL

David Dopf, JD

Executive Director & Executive Counsel, US Human Pharma Business Law, Boehringer Ingelheim, Ridgefield, CT

Liz Fowler, PhD, JD

Scholar, Johns Hopkins Bloomberg School of Public Health; Former Director, CMS CMMI (Biden); Former Special Assistant to President Obama, Washington, DC

Galina Free, MSc

Head of Trade Compliance, Danaher; Former Global Tax and Customs, Cisco, Bellevue, WA

Jeffrey Handwerker, JD

Partner, Arnold & Porter; Lead Author, “HHS-OIG Guidance on Manufacturer DTC Platforms and Congressional Pushback”, Washington, DC

Erin Hertzog, JD, MPH

Partner, Manatt, Phelps & Phillips LLP; Former Attorney, Office of the General Counsel, CMS Division, US DHHS; Former Director, Health Law & Policy, Biotechnology Industry Organization, Washington, DC

Mary Kohler, JD

Founder and Principal, Kohler Health Law, PC; Former Expert Counsel, Worldwide Compliance & Business Ethics, Amgen; Former Assistant General Counsel, GSK, Los Angeles, CA

Kristi Martin, MA, MPH

Founder, Highway 136 Consulting; Former Chief of Staff for Medicare, CMS; Former Health Care VP, Arnold Ventures, Washington, DC

Rosemary Maxwell, JD

Counsel, Arnold & Porter; Coauthor, “Trump Administration Issues Executive Order to Lower Prescription Drug Costs”, Washington, DC

Roger McCrary, JD

Senior Trade Counsel, Becton Dickinson; Former Vice President of Global Compliance, Momentive; Former Global Trade Compliance Program Leader, Medtronic, Oakland, MI

Tracy Mumpower

Director Managed Services, Helio Health Group; Former Manager, Commercial Contract Administration, King Pharmaceuticals, Bristol, VA

William Newton

Associate Editor/Senior Writer, 340B Report; Senior Healthcare Reporter, GlobalData Healthcare, Washington, DC

Sayeh Nikpay, MPH, PhD

Associate Professor, School of Public Health, University of Minnesota; Lead Author, “When Safety-Net Programs Compete: Medicaid, 340B, and the Battle Over Drug Discounts”, Minneapolis, MN

Lindsay Pronley

Director Managed Services, Life Science Revenue Management, Government Pricing & Commercial Contacting, Helio Health Group, Milwaukee, WI

Nikki Reeves, JD

Partner and Co-chair, Life Sciences and Healthcare Industry Group, King & Spalding, Washington, DC

James Robinson, PhD

Schaeffer Professor of Health Economics & Director, Berkeley Center for Health Technology, University of California, Berkeley; Author, “Most Favored Nation Pricing is an Idea whose Time has Come”, Berkeley, CA

Avik S. A. Roy

Co-Founder & Chairman, The Foundation for Research on Equal Opportunity; Chief Strategy Officer, Strive; Former Advisor, Presidential Campaigns of Marco Rubio, Rick Perry, and Mitt Romney, Austin, TX

Gillian M. Russell, JD

Counsel, FDA & Life Sciences Practice, King & Spalding; Former Consultant, Corporate Executive Board, Washington, DC

Valinda Rutledge, MBA

Executive Vice President, Policy and Advocacy, America’s Physician Groups; Former Group Director, Patient Care Model Group and BPCI Lead, CMS, Washington, DC

William Sarraille, JD

Select Counsel, Rare Access Action Project (RAAP); Facioscapulohumeral Muscular Dystrophy (FSHD) Society; and AIDS Drug Assistance Programs (ADAPs); Former Partner, Sidley Austin, Washington, DC

John Shakow, JD

Pharmaceutical Government Price Reporting Expert; Partner, FDA & Life Sciences Practice, King & Spalding LLP, Washington, DC

Joshua M. Sharfstein, MD

Vice Dean, Johns Hopkins Bloomberg School of Public Health; Former Secretary, Maryland’s Health Department; Former Principal Deputy Commissioner, US FDA, Baltimore, MD

Neena Shenai, JD

Partner, WilmerHale; Former Chief Legal Counsel and Head of Compliance for Global Trade, Medtronic; Former Trade Counsel, Ways and Means Committee, US House of Representatives, Washington, DC

Nick Shipley

Founder, Cronus Consulting; Former EVP, Biotechnology Innovation Organization (BIO); Former VP, Pharmaceutical Researchers and Manufacturers Association (PhRMA); Former Legislative Director, US House of Representatives, Washington, DC

Joseph Skupen, CPA

Managing Director, Senior Advisor and Technical Leader, Helio Health Group; Former Director FMV Tiering Global Medical Affairs, Sanofi, Berwyn, PA

Mariana P. Socal, MD, PhD, MPP, MSc

Associate Professor, Bloomberg School of Public Health and Carey Business School, Johns Hopkins University; Co-author, “Comparative Approaches to Drug Pricing” and “Tariffs as a Hidden Tax: Price Pass-Through in Multi-Stage Supply Chains”, Baltimore, MD

Ian Spatz, MPA, JD

Principal, Rock Creek Policy Group; Former Vice President, Public Policy, Merck, Author, “Most Favored Nation Drug Pricing: Aiming at Pharma’s Achilles Heel”, Washington, DC

Arun Venkataraman, MA, JD

Partner, Covington; Former Assistant Secretary of Commerce, US and Foreign Commercial Service, International Trade Administration; Former Counselor to the Secretary, US Department of Commerce, Washington, DC

A HYBRID CONFERENCE AND INTERNET EVENT